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Abstract
Atherosclerosis is a chronic inflammatory process that, in the presence of hyperlipidaemia, promotes the formation
of atheromatous plaques in large vessels of the cardiovascular system. It also affects peripheral arteries with major
implications for a number of other non-vascular tissues such as the skeletal muscle, the liver and the kidney. The
aim of this review is to critically discuss and assimilate current knowledge on the impact of peripheral
atherosclerosis and its implications on skeletal muscle homeostasis. Accumulating data suggests that manifestations
of peripheral atherosclerosis in skeletal muscle originates in a combination of increased i)-oxidative stress, ii)-
inflammation, iii)-mitochondrial deficits, iv)-altered myofibre morphology and fibrosis, v)-chronic ischemia followed
by impaired oxygen supply, vi)-reduced capillary density, vii)- proteolysis and viii)-apoptosis. These structural,
biochemical and pathophysiological alterations impact on skeletal muscle metabolic and physiologic homeostasis
and its capacity to generate force, which further affects the individual’s quality of life. Particular emphasis is given
on two major areas representing basic and applied science respectively: a)-the abundant evidence from a well-
recognised atherogenic model; the Apolipoprotein E deficient mouse and the role of a western-type diet and b)-on
skeletal myopathy and oxidative stress-induced myofibre damage from human studies on peripheral arterial disease.
A significant source of reactive oxygen species production and oxidative stress in cardiovascular disease is the
family of NADPH oxidases that contribute to several pathologies. Finally, strategies targeting NADPH oxidases in
skeletal muscle in an attempt to attenuate cellular oxidative stress are highlighted, providing a better
understanding of the crossroads between peripheral atherosclerosis and skeletal muscle pathophysiology.
Keywords: Atherosclerosis, Apolipoprotein E, NADPH oxidases, Oxidative stress, Peripheral arterial disease, Skeletal
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Background
Hyperlipidaemia – defined as increased levels of lipids
and/or lipoproteins in blood – is a major risk factor of
atherosclerosis and cardiovascular disease as well as an
independent risk factor for peripheral arterial disease
(PAD) [1, 2]. Atherosclerosis exhibits systemic manifesta-
tions not only in the large vessels of the heart (e.g.
coronary arteries) but also affects peripheral vessels [3, 4].
Atherosclerosis in peripheral arteries has a considerable
impact on skeletal muscle pathophysiology. PAD patients
exhibit a myopathy in the affected limbs, as a result of
increased oxidative damage and mitochondrial dysfunc-
tion. As the disease progresses patients show myofibre
degeneration, fatty acid deposition, fibrosis and decreased
capillarisation [5–9]. These features are followed by
intermittent claudication, reduced exercise tolerance and
ambulation that compromise the quality of life of PAD
patients [10–14].
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The transport of triglycerides, chylomicrons, chylo-
micron remnants and other lipids through the lymphatic
and circulatory system is regulated by apolipoproteins.
These proteins bind with lipids and phospholipids to
form lipoprotein complexes in a variety of sizes accord-
ing to the relative amounts of lipids and proteins they
incorporate [15]. Lipoprotein complexes are composed
mainly of triglycerides, cholesteryl esters and a small
portion of lipid soluble vitamins, while their surface is
covered by phospholipids, unesterified cholesterol and
apolipoproteins [16]. In addition, apolipoproteins act as
cofactors or activators of enzymes that are involved in
cholesterol metabolism, by mediating cholesterol esteri-
fication and lipid catabolism [17]. As a result of their
role in lipoprotein metabolism, apolipoproteins are
important contributors to plasma lipid homeostasis and
are used in the prognosis of coronary artery disease [18].
However, mutations of apolipoprotein genes B (APOB)
or E (APOE) lead to familial hypercholesterolaemia or
dysbetalipoproteinaemia; diseases that are associated
with premature atherosclerosis [19].
Apolipoprotein E (APOE) regulates blood lipid and
lipoprotein levels in multiple ways, including acting as a
ligand for low-density lipoprotein receptor (LDLR), the
transfer of lipoproteins to the liver, the formation of
chylomicrons and very low-density lipoproteins (VLDL)
as well as affecting the activities of hepatic and lipopro-
tein lipases [20, 21]. However, its functions extend far
beyond the regulation of lipid metabolism. Recent
evidence suggests that APOE plays a role in normal
brain function and a number of cardiovascular, neurode-
generative (such as Alzheimer disease, Parkinson’s
disease and multiple sclerosis) as well as metabolic (e.g.
type 2 diabetes mellitus) diseases [20]. ApoE deficiency
in mice has been also shown to result in spontanenous
atherosclerotic plaque formation also seen in humans
with severe hypercholesterolaemia (reviewed in [22]). In
turn, atherosclerosis is a chronic disorder that is associ-
ated with cellular inflammation and oxidative stress.
Reactive oxygen species (ROS) elicit cellular damage by
initiating chemical chain reactions such as lipid
peroxidation, protein oxidation as well as DNA damage
[22, 23]. Increased ROS production is one of the major
contributors of atherosclerosis that leads to endothelial
dysfunction. Nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidases (Noxs) have received a lot of
attention due to their contribution in ROS production
and nicotinamide adenine dinucleotide phosphate oxi-
dase 2 (Nox2) in particular has been shown to be
involved in atherosclerotic lesions [24–26].
The aim of this review is to critically discuss and
assimilate current knowledge on the impact of periph-
eral atherosclerosis and its implications on skeletal
muscle homeostasis. Accumulating data suggest that
manifestations of peripheral atherosclerosis in skeletal
muscle originate in a combination of increased i) oxida-
tive stress, ii) inflammation, iii) mitochondriopathy, iv)
altered myofibre morphology and fibrosis, v) chronic is-
chemia followed by impaired oxygen supply, vi) reduced
capillary density and vii) apoptosis [6, 7, 9, 27]. These
biochemical and pathophysiological alterations impact
on skeletal muscle’s metabolic and physiologic homeo-
stasis and in turn on its capacity to generate force which
may further affect the individual’s quality of life. Particu-
lar emphasis is given on i) the abundant evidence from
the ApoE deficient mouse model and the role of
western-type of diet and ii) on skeletal myopathy and
oxidative stress-induced myofibre damage from human
studies. At last, recent findings from experimental
models of atherosclerosis regarding the role of NADPH
oxidases in atherothrombotic disease are discussed in
detail.
Biological functions of apolipoprotein E
Apolipoprotein E is synthesized by several tissues, pri-
marily the liver, brain, adrenal glands, adipose tissue,
kidney and macrophages [28–30]. APOE associates with
triglyceride-rich proteins such as VLDL and chylomi-
crons as well as a subset of high-density lipoproteins
(HDL) [31, 32]. It also serves as a ligand for the LDL re-
ceptor, LDL receptor related protein 1, APOE receptor 2
and heparan sulfate proteoglycans [33–35]. The human
APOE gene is located on chromosome 19 and is com-
prised of four exons and three introns [31]. APOE is
synthesized as a 319 amino acid propeptide and under-
goes mucin-O-type glycosylation in the Golgi apparatus,
giving rise to the mature APOE protein consisting of
299 amino acids with a molecular weight of ~34.5 kDa
[31, 34, 36]. The APOE gene has two polymorphisms at
a single locus that lead to three APOE alleles, ɛ2
(APOE2), ɛ3 (APOE3) and ɛ4 (APOE4) [34]. The differ-
ent combination of the above alleles gives rise to three
heterozygous and three homozygous phenotypes [37].
APOE3 is the most prevalent isoform and is considered
to be the allele that all other variants have derived from
[34]. APOE2 and APOE4 are associated with several
inflammatory diseases [38]. APOE2, in particular, corre-
lates with the genetic lipid disorder type III hyperlipo-
proteinaemia and high plasma triglyceride levels [39].
APOE4 on the other hand, correlates with increased
plasma levels of LDL, thus contributing to a higher risk
for developing cardiovascular disease and is also associ-
ated with the initiation of Alzheimer’s disease [37–40].
The key role of APOE in atherosclerosis has been
reviewed previously [21, 28, 32, 34, 41, 42].
APOE has a major anti-atherogenic function, as it reg-
ulates plasma homeostasis by promoting the clearance
of lipoproteins, chylomicrons and their remnants,
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induces VLDL secretion from the liver as well as the re-
verse cholesterol efflux of VLDL and chylomicron rem-
nants from the liver and macrophages [28, 37, 42]. The
key role of APOE in lipoprotein metabolism is brought
about by the activation of enzymes that are essential for
lipoprotein breakdown. In addition to the lipoprotein
metabolism, APOE exhibits anti-atherogenic activity by
inhibiting platelet aggregation in the vessel wall and in-
duces proliferation of T lymphocytes, endothelial cells
and vascular smooth muscle cells [34]. Apart from its
anti-atherogenic role and regulation of lipoprotein me-
tabolism, APOE has been shown to be neuroprotective,
as well as acting as an antioxidant and immunomodula-
tor by suppressing type I inflammatory response and
inducing the M2 anti-inflammatory pathway in macro-
phages [31, 33, 34, 43]. Furthermore, accumulating data
report that APOE is involved in adipogenesis by indu-
cing the assembly of triglycerides in the adipocytes [39].
Therefore, ApoE deficiency has been used extensively in
experimental studies of atherosclerosis.
Manifestations of ApoE deficiency in the
cardiovascular system
APOE deficiency in humans is a rare phenomenon but
has a broad range of phenotypes spanning from mild
hypercholesterolaemia to severe xanthomatosis, hyperli-
poproteinaemia and development of premature athero-
sclerosis [37, 41, 44, 45]. Similarly, ApoE deficiency in
mice (ApoE-/-) leads to hyperlipidaemia and spontaneous
development of atherosclerotic lesions from the age of
10 weeks, designating the ApoE-/- mouse model as one
of the best established experimental tools to study ath-
erosclerosis [46, 47]. Consequently, a plethora of studies
conducted in ApoE-/- mice has addressed the impact of
the initiation and progression of atherogenesis on the
vascular system [48–51].
The majority of cholesterol in the ApoE-/- mice is dis-
tributed in VLDL and intermediate density lipoproteins
(IDL)/LDL particles [52, 53]. It is well known that
plasma cholesterol and particularly VLDL and IDL rem-
nants are significantly elevated in ApoE-/- mice as sum-
marised in Table 1 (e.g. [47, 49]). Compared to wild type
mice, total plasma cholesterol levels increase by 3- to 7-
fold – depending on the study and the age of mice–
while plasma triglycerides show an up to twofold in-
crease [47, 54–56]. LDL increases by 4– to 14–fold and
VLDL and IDL remnants by 10– to 18–fold [47]. There
are conflicting data with regards to HDL levels that have
been shown to decrease, remain unchanged or even in-
crease [45, 48, 55, 57, 58]. Tani et al. reported that
ApoE-/- mice not only have lower levels of HDL choles-
terol, but the HDL particles are significantly altered in
their composition [45].
Due to their hyperlipidaemic profile, ApoE-/- mice de-
velop atherosclerotic lesions at a young age. Monocytes
begin to adhere to the vascular wall at the age of 6–8
weeks and approximately after 2 weeks; foam cells and
lesions are observed leading to atherosclerotic plaques
[22, 59, 60]. Plaque formation is apparent initially in the
proximal aorta and progressively expands throughout
the aorta showing diversity in the size, number and com-
plexity [61]. At the onset of atherosclerotic lesion, in-
flammation is augmented in the aorta [22]. Specifically,
vascular cell adhesion molecule 1 expression (VCAM1)
from aortic endothelial cells is increased and a signifi-
cant upregulation of genes that are involved in inflam-
mation and proteolysis is observed from the age of
12 weeks [61, 62]. Apart from increased inflammation in
the aorta, there is evidence of oxidative stress, impaired
mitochondrial respiration and mitochondrial DNA dele-
tion that increases by 3–fold at a later age [63–67].
Nonetheless, antioxidant protein expression in the aorta
is not altered at the age of 10 weeks [64].
As atherosclerotic lesions advance with age, plasma
levels of VLDL and LDL either increase or remain un-
changed [49, 68]. Peritoneal macrophages that form
lipid–laden foam cells exhibit decreased expression of
ATP–binding cassette transporter A1 and Scavenger re-
ceptor type B1 –both contributors of anti-atherogenic
properties in macrophages–and increased expression of
Cluster of Differentiation 36–a receptor with pro-
atherogenic functions and thus may further contribute
to lesion progression [49]. Along with the lesion pro-
gression in size and composition, the endothelium is se-
verely damaged with increased leakage, loss of tight
junctions of endothelial cells and increased repair, while
Table 1 Overview of blood lipid and lipoprotein changes in response to ApoE deficiency and/or western-type diet
ApoE-/- ND vs. WT ND ApoE-/- WD vs. WT WD
Total Cholesterol ↑ 3–7fold [48, 52, 54, 287] ↑ 2–18fold [48, 52, 54, 99, 100, 287]
VLDL/IDL ↑ 10fold [52, 54, 79, 95] ↑ 10–30fold [47, 52, 54, 95]
LDL ↑ 4-14fold [58, 79, 95] ↑ 3–14fold [47, 54, 95]
TGs ↑ 0–4fold [48, 52, 54, 58, 100, 287] ↑ 0–2fold [48, 52, 54, 58, 100, 287]
HDL ↓ 0–1.7fold [15, 48, 58, 79, 95] ↓ 0–2fold or ↑3fold [48, 52, 95, 98, 103]
Abbreviations: HDL High-density lipoprotein, LDL Low-density lipoprotein, ND Normal chow diet, VLDL/IDL Very low-density lipoprotein/Intermediate density lipo-
protein, TGs Triglycerides, WD Western-type diet, ↑Increase, ↓Decrease
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a decrease in endothelial progenitor cells that are in-
volved in vascular repair is observed [69, 70]. At
13 months of age, ApoE-/- mice exhibit a 61% occlusion
of the lumen and decreased endothelial-dependent
relaxation to acetylcholine, an increase in stiffness of
conduit arteries leading to elastic laminar fragmentation,
while endothelium independent relaxation remains in-
tact [68, 71–74]. In contrast to humans, the impairment
in endothelium dependent vasodilation in ApoE-/- mice
appears to be focal rather than systemic [47, 75].
Additionally, the extend of mitochondrial DNA deletion
in the aorta is greater as shown by decreased mRNA and
protein levels of 8-oxyguanine glycosylase – a DNA
repair enzyme [66].
At 17–18 months of age, lumen occlusion can reach
90% and lesions are found mostly in the aortic arch,
aortic root and in the proximal and distal segments of
thoracic aorta, while small lesions appear in the central
thoracic aorta [59, 72, 76]. Moreover, lipid deposition is
further augmented and vascular senescence appears
mainly in the aortic arch, a site with turbulent blood
flow, and as a compensatory mechanism for maintaining
the diameter of the vessel positive remodelling is
observed in the aorta [56]. Hence, atherosclerosis in
ApoE-/- mice advances in an age-dependent manner and
lesion composition and progression is very much similar
in humans [47, 77]. It is worth mentioning that even
though there is a significant similarity in the atheroscler-
otic process between ApoE-/- mice and humans, ApoE-/-
mice do not develop lesions in the coronary arteries as
humans [59, 61]. Many studies have shown an increased
heart-to-body mass ratio (an index of cardiac hyper-
trophy), left ventricular hypertrophy and increased diam-
eter of the posterior wall from the age of 13 weeks that
progress with age [73, 78–80]. In parallel, 10 month-old
ApoE-/- mice exhibit dilated cardiomyopathy charac-
terised by impaired left ventricular function and in-
creased fibrosis of the myocardium and endocardium
[68]. Although ApoE-/- deficiency in combination with
ageing and diet seem to impact on cardiac morphology
[22], there is a number of studies that failed to report
cardiac phenotypic changes [56, 81, 82], suggesting that
other variables may play a role in the multifactorial
development of a cardiac phenotype.
The progression of atherosclerosis may be regulated
by sex [47]. Some evidence suggests that there is a
significant difference in total plasma cholesterol and tri-
glyceride levels between male and female ApoE-/- mice
of the same age and diet, with male mice displaying
higher levels [54, 56, 77]. However, this finding has not
been confirmed by others [83, 84]. Furthermore, many
groups have reported that lesion surface area in the
aorta of male mice is greater than in females and Chiba
et al. (2011) suggest that the difference might be due to
increased activity of neutral cholesterol ester hydrolase
by estradiol in the aorta and peritoneal macrophages
[49, 56, 83, 85]. Studies in gonadectomised female
ApoE-/- mice showed that the lesion burden in the aortic
sinus and abdominal aorta was greater that in control
ApoE-/- mice, while estradiol 2 treatment of gonadecto-
mised male and female ApoE-/- mice led to a 50%
decrease of lesion area throughout the aorta [86, 87]. On
the contrary, other studies report that lesion coverage is
either greater in female than in male mice or no correl-
ation is found based on sex [59, 77, 88, 89]. In a recent
study using western-type diet, female mice had greater
endothelial dysfunction in the coronary arteries than
male mice [84]. Taken together, the above data suggest
that although the male sex can affect the progression of
atherosclerosis there may be other contributing variables
such as diet that play a role in atherogenesis and
additional research is warranted.
High-fat and western-type diets accelerate athero-
sclerosis in ApoE deficiency
High-fat diets are usually composed of 15–36% w/w fat
which corresponds to 34–60% kcal from this source
containing mostly saturated fats [90–95]. However, sev-
eral studies use the term “western diet” in an attempt to
draw parallels with the dietary composition of modern
societies, which are rich in fat and cholesterol. A
western-type diet is typically composed of 21% w/w fat
that corresponds to 40–45% kcal from fat supplemented
with 0.15–1.25% cholesterol [53, 96]. High-fat and
western-type diets have both been used in ApoE-/- mice
and abundant evidence suggests that such dietary
challenges result in aggravation of the atherosclerotic
phenotype [61, 95, 97].
One to eight weeks on a western-type diet increases
total plasma cholesterol levels by 3- to 7-fold and
atherosclerotic lesions in the aortic sinus are evident
from the fourth week in young ApoE-/- mice [48, 98].
Western-type diet administration for larger periods such
as 24 weeks results in total cholesterol levels of 1200–
1400 mg/dL, representing a 12- to 18-fold change com-
pared to wild type mice or a 5-fold change compared to
ApoE-/- mice kept on a chow diet, although absolute
levels of total cholesterol vary amongst studies as shown
in Table 1 [48, 98–100]. Aortic lesion coverage after
5 weeks of a western-type diet is minimal, approximately
1.8%, and reaches 5.5% after 12 weeks [57]. However, the
abdominal aorta lesion coverage after 14 weeks of west-
ern-type diet reaches 19% and after 24 weeks the plaque
surface area covers about 60% of the aorta [50, 98]. Ath-
erosclerosis is considered an inflammatory process and
expression of pro-inflammatory molecules such as inter-
cellular adhesion molecule 1 (iCAM–1) and C-C motif
chemokine receptor 2 protein and mRNA expression of
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interleukin 6, interleukin 17 and inducible nitric oxide
synthase in the aorta appear to be augmented from
the second week of western-type diet, in the absence of
changes in plasma pro-inflammatory cytokines interleukin
6 and 10 and tumour necrosis factor α (TNFα) [48, 50, 98].
Other inflammatory markers, such as interleukins 1α, 1β
and VCAM-1, are also elevated in the aorta [101, 102].
However, others have not observed alterations in iCAM–1
levels in endothelial cells before 20 weeks of a western-type
diet [61]. Apart from macrophage infiltration, Type 1, Type
2 and regulatory T-helper lymphocytes cells are also re-
cruited in the aorta, with T-helper Type 2 (Th2) cells redu-
cing after 10 weeks of a western-type diet whereas T-helper
Type 1 (Th1) lymphocytes and regulatory T-helper cells re-
main in the lesions [50]. Th1 lymphocytes notably exhibit
pro-inflammatory properties whereas Th2 and regulatory T
helper cells are anti-inflammatory [50]. Further to the
increase of Th1 cells, upregulation of T-helper Type 17
(Th17) cells and subsequent expression of interleukin 17
that advocates atherosclerosis are apparent in the aorta and
as the duration of a western-type diet advances, Th17 and
Th1 cells accrete in splenocytes, suggesting that there is a
systemic upregulation of T helper lymphocytes [98, 103].
Along with increased inflammation, increased oxida-
tive stress is also evident. By 7 weeks of western-type
diet, reactive oxygen species production increases by 2-
fold in the aorta and after 8 weeks there is a 4-fold
increase in the media of the aorta and a 3-fold increase
in the perivascular fat of the ascending aorta [48, 57].
This increase has been mainly attributed to enzymes
that generate ROS. Nox2 expression is increased by
3-fold in macrophages and endothelial cells and
xanthine oxidase expression is augmented in macro-
phages, endothelial cells and smooth vascular cells
[57, 102]. After 12 weeks on the western-type diet
there are elevated markers of oxidative stress not only
in the aorta, but also in plasma [101]. Moreover, hyp-
oxia is considered to contribute in plaque progression
possibly through the induction of several genes that
are involved in inflammation, redox homeostasis,
apoptosis and neovascularisation. Evidence is based
on the expression of hypoxia inducible factor 1α
(HIF1α) and its downstream targets vascular endothe-
lial growth factor (VEGF) and glucose transporter 1
specifically in the central regions of lesions, where
oxygen supply is attenuated after a 16- or 30-week
western-type diet challenge [97, 104].
Endothelial dysfunction is evident from the fifth week of
western-type diet and in particular, endothelium-dependent
relaxation to acetylcholine is impaired in the proximal de-
scending aorta whereas it remains unaltered in the thoracic
aorta [105, 106]. Endothelial nitric oxide synthase (eNOS)
and protein kinase B phosphorylation levels are decreased
in the aorta of ApoE-/- mice after 16 weeks of western-type
diet when compared to the wild type mice on a chow diet
[107]. Conversely, ApoE-/- mice fed a western-type diet for
20 weeks have increased eNOS protein expression in aortas
when compared to wild type fed the same diet, potentially
as a compensatory mechanism against the increased ex-
pression of Nox2 that reduces nitric oxide bioavailability
[108]. Endothelium-dependent relaxation to acetylcholine
is further impaired after 30 weeks of western-type diet and
the impairment is possibly due to decreased Ca2+
dependent eNOS activity as judged by decreased basal
levels of cyclic guanosine monophosphate [109]. The wall
of the aorta increases in thickness and stiffness as the dur-
ation of the western-type diet extends, as shown from in
situ extension-inflation tests [97]. In resistance vessels, such
as mesenteric arteries, endothelium-dependent and endo-
thelium independent vasodilation are impaired and there is
an increase in wall thickness and cross sectional area pos-
sibly because of increased expression of vasoconstrictors
such as endothelin 1 (ET-1) [109, 110]. Similarly, in carotid
arteries after 12 months of a western-type diet, positive re-
modelling is observed that is inadequate to compensate for
the decrease of lumen diameter and over 70% stenosis is
apparent, followed by a decline in vasodilation to acetylcho-
line and nitric oxide [111].
In addition to endothelial dysfunction, increased in-
flammation and oxidative stress, there is evidence that
ApoE deficiency may impact on cardiac muscle per se.
Standard chow diet supplemented with 0.15% w/w chol-
esterol for 18 months induces cardiac hypertrophy
followed by impaired cardiac function which is charac-
terised by a reduced ejection fraction and a reduced
maximum rate of change of left ventricular pressure
[112]. In turn, a western-type diet to 40 week old mice
results in increased cardiomyocyte size and subsequent
cardiac hypertrophy, an age-dependent increase in left
ventricular mass, followed by increased collagen volume
and myocardial fibrosis [60, 113, 114]. However, other
studies failed to detect any changes in the heart-to-body
weight ratio after 30 weeks of western-type diet [84,
98]. This discrepancy may be due to the diet compos-
ition, atherogenicity of the diet (i.e. cholesterol
amount) as well as the experimental diversity regard-
ing the animal age.
Apart from the ApoE-/- mice, LDL receptor defi-
cient (Ldlr-/-) mice represent another model of
systemic atherosclerosis that shows mechanistic differ-
ences in the development of atherosclerosis reviewed
elsewhere [54, 93]. In brief, Ldlr-/- mice on a chow
diet have also increased total plasma cholesterol but
lesion formation is rather observed in aged animals
and is limited to the aortic root, whereas in ApoE-/-
mice lesions form at 8–10 weeks of age and subse-
quently develop throughout the aorta. When ApoE-/-
mice are fed a western-type diet total plasma
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cholesterol is further augmented and lesions form at
an earlier age (i.e. 4–6 weeks old) and progress more
rapidly [93, 115, 116]. Conversely, Ldlr-/- mice fed an
atherogenic diet for 12 weeks, develop lesions in the
aortic root and increase thereafter robustly extending
to the thoracic and abdominal regions of the aorta
[115, 117]. Another difference between the two ath-
erosclerotic models is that ApoE-/- mice subjected to
either a chow- or an atherogenic- diet carry most of
their cholesterol in the apoB48-containing VLDL par-
ticles, whereas Ldlr-/- mice on a chow diet have pre-
dominantly apoB100-containing LDL particles, a
feature that is more relevant to human pathogenesis
of atherosclerosis [54, 93]. However, when challenged
with an atherogenic diet, Ldlr-/- mice exhibit in-
creased LDL as well as VLDL particles [93, 118]. Fur-
thermore, ApoE is a lipoprotein that not only
contributes to lipid homeostasis but has several other
functions (such as immunomodulator and antioxidant)
as discussed in a previous section. Therefore, findings
in the ApoE-/- mice may be attributed not only to the
plasma lipid levels but also to the loss of the anti-
atherogenic functions of ApoE [93, 119].
Beyond the well-documented evidence on the detri-
mental effects of atherogenic diets with regards to the
cardiovascular system and progression of atherosclerosis,
there has recently been an expansion of interest on new
areas that will be discussed below. Emphasis is given on
i) the manifestations of atherosclerosis in peripheral tis-
sues such as skeletal muscle and ii) the role of Noxs in
vascular disease and the subsequent potential emerging
from strategies to attenuate vascular oxidative stress by
targeting NADPH oxidases.
Manifestations of peripheral atherosclerosis in
human skeletal muscle
Skeletal muscle constitutes one of the largest tissues in
the human body comprising of almost 40% total body
weight [120]. Skeletal muscle is a very dynamic and
adaptable tissue that accounts for up to 40% of the
metabolic rate at rest in humans and provides for 30–
50% of protein turnover for the whole body [121]. The
main role of skeletal muscle is to generate force and
movement which is accomplished by turning chemical
energy (ATP) into mechanical energy. Apart from the
production of mechanical energy, muscle exhibits mul-
tiple metabolic functions [122]. It serves as a reservoir of
amino acids that are used by other tissues, generates
body heat, has a high capacity of oxidative metabolism
and represents the major peripheral tissue in insulin-
mediated glucose uptake as well as glycogen and trigly-
ceride storage [120, 123]. Therefore, skeletal muscle
homeostasis is not only important in health but also in
disease. Beyond the extensive research in central
atherosclerosis, recent studies have focused on the effect
of atherosclerosis on skeletal muscle, with most of the
evidence emerging from human patients with peripheral
arterial disease, as summarised in Table 2. PAD is a
chronic degenerative condition that is characterised by
vascular deficits leading to restriction and blockage of
the arteries of the lower extremities and skeletal myop-
athy [5, 124]. The clinical manifestations of PAD are
categorised in: i) intermittent claudication (IC), where
leg pain occurs with physical activity but is alleviated at
rest and ii) critical limb ischemia (CLI), where leg pain
occurs at rest with or without tissue necrosis or
gangrene [125, 126]. PAD is associated with increased
cardiovascular morbidity and mortality and impaired
quality of life. However, there is limited data (Table 3)
on the underlying pathophysiology of skeletal muscle,
which is often overlooked [127, 128]. Although restric-
tion of blood flow was considered the most important
factor of IC and CLI symptoms, recent studies suggest
that it is probably not the only cause of functional im-
pairment [124, 129–133]. Most emphasis has been given
to the study of ischemia–reperfusion cycles that are con-
sidered an important contributor in skeletal muscle
pathophysiology in PAD [134]. Emphasis is also placed
on the pathophysiology of PAD and those factors that
may lead to clinical manifestation of PAD including sys-
temic inflammation, comorbidities, oxidative stress and
mitochondrial deficits [125, 126, 128, 131, 135]. Current
evidence on the effect of PAD in capillaries and skeletal
muscle is discussed in this section (Fig. 1).
Oxidative stress
As discussed above, central atherosclerosis is a chronic in-
flammatory disease that leads to plaque formation and oc-
clusion of major arteries, initiated by increased oxidative
stress and pro-inflammatory signalling that lead to endo-
thelial dysfunction [2, 5, 136, 137]. However, accumulating
evidence indicates that these two processes are inextric-
ably intertwined and oxidative stress promotes cellular in-
flammation not only in aorta but also in skeletal muscle.
This is partially attributed to a mechanism mediated by
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) that promotes pro-inflammatory signalling
and in turn amplifies oxidative stress via the production of
reactive oxygen species [138]. Certain levels of ROS that
are produced during muscle contraction are considered as
important regulators of muscle function by activating
pathways that regulate key homeostatic processes includ-
ing myogenesis, muscle remodelling, regeneration, protein
synthesis and substrate metabolism [139]. For example,
ROS regulate glucose metabolism by activating the 5′ad-
enosine monophosphate-activated protein kinase and
initiating the mitogen-activated protein kinase signalling
cascade [139]. However, excessive ROS production is
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Table 2 Skeletal muscle deficits in patients with peripheral arterial disease
Reference Intervention Findings
[10] 62 ± 2 yr; IC > 1y; ABI: 0.58 ± 0.03; GT test→muscle biopsy
of gastrocnemius
↓ maximal walking time, peak power, ABI, VO2 in PAD limbs; ↓ type I ↑ IIA
fibres; ↔ IIB; 9% ↓ CSA; ↔ Capillary to fibre ratio; ↔ Muscle glycogen
[151] 68–71 yr; ABI: 0.64 ± 0.04; ↑ Smokers in PAD group; GT
test→muscle biopsy of gastrocnemius
↓ Mitochondrial activity of complex I and III;
[27] IC group with ABI = 0.35 ± 0.06; CLI group with ABI =
0.27 ± 0.05; Muscle biopsy of Gastrocnemius; More male in
all groups; ↑ smokers, diabetes, hypertension in both PAD
groups; ↓ obese in both PAD groups
Features of progressive muscle degeneration (i.e. myofibre atrophy, loss
of the polygonal fibre shape, nuclear clumps, ↑ central nucleation, fibre
vacuolization, target lesions, myofibre regeneration, myofibre necrosis
and fibrosis and replacement of muscle by adipose tissue;
[190] CLI; Study of popliteal arteries after amputation ↑ ET-1 plasma levels by 4-fold and ‘locally’ in femoral artery; ↑
atherosclerosis in popliteal arteries; ET-1 & receptors ETA ETB were
associated with the luminal endothelium, ECs of the adventitial vasa
vasorum and neural microvessels. ETA receptor similar in distribution
to ET-1, co-localising with macrophages.
[148] Diabetes, Hypercholesterolaemia,
Hypertension; 76 yrs old; Grade III (intermediate), IV and V
(advanced) lesions; Femoral artery samples
↑ inflammation in both stages, with different gene expression patterns;
↑ proteolysis and anti-proliferation markers & ↓ cell metabolism,
catabolism in intermediate stage; ↑ vascular extracellular matrix markers
& ↓ markers of protein folding, apoptosis, protein modification in
advanced lesions
[150] ABI = 0.55 ± 0.21; Age & sex matched; Diabetes, CAD,
Dyslipidaemia, Hypertension; ↑ Smokers in PAD group;
Muscle biopsy of gastrocnemius
↑ desmin by 21.5%; Abnormal morphology of myofibres with ↓ CSA,
Negative correlation between CSA, morphology and desmin content;
↓ mitochondrial respiration from complex I and IV with irregular
distribution; Negative correlation between isometric plantarflexor
strength and desmin
[6] Sex & Aged Matched; Type I Diabetes,
CAD, Dyslipidaemia, Hypertension; ↑ Smokers in PAD
groups Fontaine stage II (ABI = 0.53 ± 0.04) and IV
(ABI = 0.25 ± 0.04); Muscle biopsy of gastrocnemius
↑ 25% of carbonyl content in all fibre types, mostly in type II fibres
for all PAD patients; ↓ CSA; ↑ carbonyl content in PAD-IV vs. PAD-II
patients; ↑ damage in type II fibres in PAD-II, whereas in PAD-IV type
II and I/II had equal damage; Shift from type II to type I for both stages;
[141] Age & Sex Matched; ↑ Smokers, Diabetes, CAD, Hypertension
& Dyslipidaemia in PAD group; Advanced PAD ABI =
0.34 ± 0.05; Muscle biopsy of gastrocnemius
↓ activity of complexes I, III and IV; ↓ mitochondrial respiration; ↓ protein
expression of MnSOD; ↑ Catalase, GPx activity; ↔ CuSOD activity; ↑
Carbonyl content, Lipid hydroperoxides and 4-HNE adducts; ↔
Mitochondrial number;
[155] Mean ABI = 0.4;
Lower extremities operations
↔ mitochondrial respiration in baseline; ↓ mitochondrial respiration
state 3 and 4
[9] Age & sex matched; ↑ CAD & Hypertension in PAD groups;
matched for smoking, myocardial infraction, stroke, renal
insufficiency, obesity, dyslipidaemia; Fontaine Stage II,
III and IV; ABI = 0.34 ± 0.24; Lower extremities operations
↑ carbonyl content and 4-HNE adducts in line with advanced stages
of disease; ↓ myofibre CSA; ↑ oxidative damage
[192] Age & Sex Matched; ABI = 0.6 ± 0.18; ↑ smokers and statin
treatment in PAD group; Gardner Protocol; Muscle Biopsy
of gastrocnemius
↑ apoptosis of endothelial cells in myofibres; ↑ caspase 3 expression;
[288] Age matched; ABI < 0.9 for PAD patients; Smokers,
non-diabetic; Muscle biopsy of gastrocnemius
↓ capillary density in gastrocnemius of PAD patients associated with
↓ VO2max, peak walking time and claudication onset time
[183] Age & Sex Matched; Diabetic and smokers in both CLI and
healthy control group; Muscle biopsy of gastrocnemius in
CLI and control group followed by amputation in CLI group
↑ capillary density and capillary to myofibre ratio in gastrocnemius of
CLI patients; abnormal structure of the capillaries in CLI group
[162] ABI = 0.50 ± 0.17; Smokers, non-diabetic; Muscle biopsy of
Gastrocnemius
↑ mtDNA deletion (4977 bp) deletion in both limbs but ↑↑ in the
affected limb; ↑ other mtDNA deletions
[184] Sex Matched; ↑ Age in PAD group; ABI = 0.64 ± 0.2; Muscle
biopsy of gastrocnemius after exercise
↔ VEGFA concentration; ↔ VEGF165b; ↔ VEGFR1 concentration; ↓
capillaries in IC
[182] Age matched; only male; CAD, Dyslipidaemia, Diabetes;
Fontaine stage II-IV; ABI = 0.31 ± 0.25; Muscle biopsy of
Gastrocnemius
↑ FoxO1 protein levels negatively correlated with ABI
↔ FoxO3a levels; ↑ p27KIP1 and THSB1
[147] Aged matched; ↑ hypercholesterolaemia, smokers and male
in PAD group; Fontaine stage III and IV; femoral and
popliteal arteries
↑ serum PON1 and CCL2; ↑ thicker tunica intima/tunica media ratio
in femoral arteries; ↑ calcium deposits in the media; ↑ PON1, PON3,
CD68 (mainly in intima), CCL2 and its receptors DARC, CCBP2 not
CCR2 in affected arteries
[142] Fontaine stage IIa and IIb ↑ serum YKL-40 in PAD patients
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deleterious and leads to oxidative damage in the muscle
and may impact not only on cellular function but also
damage DNA, lipids and proteins [138–140]. A fine
tuning in ROS production exhibits opposing effects on
muscle homeostasis and has important implications in
health and disease states.
In fact, limb skeletal muscles of PAD patients exhibit
increased protein carbonylation and 4-hydroxy-2-none-
nal (4-HNE) adducts, which increase further as the
disease advances [6, 9, 141]. It is worth mentioning that
in the early stages of PAD (Fontaine stage II) type II
myofibres seem to be more susceptible to oxidative dam-
age than the hybrid type I/II and type I myofibres as
judged by higher protein carbonyl contents [6]. Accord-
ingly, in severe PAD (Fontaine stage IV) all myofibre
types, i.e. type II, II/I and I, have similar levels of oxida-
tive damage [6]. The oxidative damage of myofibres is
evidenced by the elevated levels in carbonyl content, 4-
HNE adducts and lipid hydroperoxides, despite an in-
crease in protein expression of key antioxidants such as
catalase and glutathione peroxidase, possibly due to a
potential compensatory mechanism [141].
Inflammation and apoptosis
Apart from increased oxidative damage, inflammation is
another major initiator of central atherosclerosis. The
Table 2 Skeletal muscle deficits in patients with peripheral arterial disease (Continued)
[163] Age & Gender Matched; ↑ hypertension in PAD group;
ABI = 0.73 ± 0.14;
↓ capillary density and ↔ capillary/fibre ratio, CSA of fibres; ↑ thickening
in basement membrane of lumina; ↓ volume of mitochondria
[143] PAD with Fontaine stage III and IV Correlation of PAD and serum cytokines for VEGF, CCL2 and TNFα
[144] Only PAD patients with ABI = 0.72 ± 0.24 (no control group) ↑ gait impairment that correlated with hsCRP and ICAM-1
[191] PAD-II (Fontaine stage II, ABI = 0.55 ± 0.22) and PAD-IV
(stage IV, ABI = 0.22 ± 0.13) vs control group; Gender
matched; Age matched only PAD-II vs control
↑ 3.5-fold in PAD-II and ↑ 8-fold in PAD-IV of TGFβ-1 vs Control; Correlation
of collagen density and stage of PAD with TGFβ-1; TGFβ-1 was expressed
only by sub-endothelial SMCs and associated with accumulation of
fibroblasts and collagen deposition
[264] PAD Fontaine Stage IIb vs control group; ↔ mRNA level and dialysate VEGF but ↓ protein in PAD vs control;
↔ mRNA levels of VEGFR-2, TSP1 and eNOS; ↑ dialysate of TSP1
[186] PAD with/without CAD and control group; PAD patients
with either IC (70%) or CLI (27%); Age/gender matched
↓↓ in PAD with/without CAD and ↓ in PAD with CAD of flow-mediated
dilation and reactive hyperaemia
[132] CLI; Amputated limbs ↑ calcification of media; lesions lacked of lipids and inflammatory cells,
with atherosclerosis being present in less than 25%; Majority had
type V, I and II lesions
[161] Patients with IC and control group; ↑ dyslipidaemia,
hypertension, CAD; age matched;
↓ glucose uptake from calf muscle in IC patients; glucose uptake correlates
with whole body insulin resistance (with/without diabetes) and not ABI
[133] PAD patients with IC and CLI (41%); Majority had type V-VII plaques in femoral arteries; Type of lesions did not
correlate with age, sex, diabetes and clinical stage; ↑ of inflammatory cells
in lesions of CLI vs IC; No correlation between calcification and clinical
stage; Correlation of SMCs and collagen deposition
[154] PAD patients with IC (ABI = 0.63 ± 0.16) and control group;
Age/gender matched; Muscle biopsy from Gastrocnemius
Heterogeneity in fibre type distribution in PAD; ↔ capillary density that
doesn’t correlate with fibre type; ↓ SDH and COX-1 activity in myofibres
due to ↑ autophagy of the intermyofibrillar mitochondria
Abbreviations and Symbols: ABI Ankle-Brachial Index, CAD Coronary Artery Disease, CCBP2 Chemokine (C-C motif) binding protein 2, CD68 Cluster of Differentiation
68, CCL2 Chemokine (C-C motif) ligand 2, CLI Critical Limb Ischemia, COX-1 Mitochondrial complex IV, subunit I, CSA Cross Sectional Area, DARC Duffy antigen/che-
mokine receptor, EPC Endothelial Progenitor Cells, ET-1 Endothelin 1, FoxO1 Forkhead Box Protein O1, FoxO3 Forkhead Box Protein O3, GT test Graded treadmill
test, hCRP high-sensitivity C-reactive protein, IC Intermittent Claudication, ICAM-1 Intercellular adhesion molecule 1, p27KIP1 Cyclin Dependent Kinase Inhibitor 1B,
PAD Peripheral arterial disease, PON1 Paraoxonase 1, PON3 Paraoxonase 3, SDH Succinate dehydrogenase, SMCs Smooth Muscle Cells, TGFβ-1 Transforming Growth
Factor β 1, THSB1/TSP1 Thrombospondin 1, TNFα Tumour Necrosis Factor α, VCAM-1 Vascular Adhesion Molecule 1, VEGF-A Vascular Endothelial Growth Factor A,
VEGF Vascular Endothelial Growth Factor, VEGFR-2 Vascular Endothelial Growth Factor Receptor 2, VO2max Maximal Oxygen Consumption, YKL-40 Chitinase-3-like
protein 1, ↑ increase, ↓ decrease, ↔ no change
Table 3 Overview of skeletal muscle deficits in intermittent claudication (IC) and critical limb ischemia (CLI)
Mild to Moderate Disease (IC) Severe Disease - Critical Limb Ischemia
Oxidative stress mainly in type II fibres [6] Oxidative stress in all fibre types [6, 27, 280]
↔/↓ capillary density, ↓ ABI (0.5–0.8)
[154, 163, 288]
↓↓ ABI (<0.4) [141]
↓ mitochondrial volume [163] Mitochondriopathy [141]
↑ TGFβ1, desmin accumulation [150, 191] ↑↑ TGFβ1, collagen [133, 191]
↔/↓ myofibre CSA [10, 163] Fibrosis, Fat accumulation, different myofibre sizes but ↓↓ CSA [27]
Abbreviations and Symbols: ABI Ankle-Brachial Index, CLI Critical Limb Ischemia, CSA Cross Sectional Area, IC Intermittent Claudication, TGFβ-1 Transforming
Growth Factor beta 1; ↑ increase, ↓ decrease, ↔ no change
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majority of studies have focused on identifying markers
of systemic inflammation and their potential role in
PAD pathophysiology [135, 142–144]. Patients with PAD
have elevated plasma levels of C-reactive protein and
inflammatory markers such as monocyte chemotactic
protein 1, D-Dimer (a fibrin degradation product), inter-
leukin 6 (IL-6), TNFα, soluble VCAM-1 and soluble
iCAM-1 are associated with an inferior performance in
the 6 min walking test [5, 143–147]. To the best of our
knowledge, studies investigating inflammation in the
skeletal muscle of PAD patients remain to be conducted
since the existing evidence is limited to the arteries of
the affected limbs.
Inflammation in lesions of femoral arteries is increased
in patients with CLI as compared with patients with IC,
is mainly localised in the intima and is characterised by
elevated number of macrophages [133, 147]. Immune
system-related genes are upregulated in PAD and gene
microarray analysis reveals different gene expression
patterns in different stages of the disease [148]. There is
also increased expression of genes regulating apoptosis
(e.g. myristoylated alanine-rich C kinase substrate,
MARCKS and phospholipid transfer protein, PLP), pro-
teolysis (e.g. cathepsin B, CTSB and cathepsin C, CTSC)
and immune function (e.g. Triggering receptor expressed
on myeloid cells 1, TREM1 and Gamma-interferon-
inducible lysosomal thiol reductase, IFI30) in intermedi-
ate lesions, whereas genes controlling cell metabolism
(e.g. glycine cleavage system protein H, GCS and
phospholipase A2 group IVA, PLA24A) are downregu-
lated [148]. In advanced lesions, vascular extracellular
matrix gene expression is upregulated (e.g. Collagen
Type I Alpha 1 Chain, COL1A1 and Collagen Type III
Alpha 1 Chain, COL3A1) and a downregulation of genes
involved in cell cycle (e.g. cysteine and histidine rich
domain containing 1, CHORD1 and Neural precursor
cell expressed developmentally down-regulated protein
9, NDD9) apoptosis (e.g. Metallophosphoesterase Do-
main Containing 2, MPPED2 and Gutaminase, GLS) and
RNA metabolism (e.g. Double-stranded RNA-specific
adenosine deaminase, ADAR) is observed [148]. Another
difference between the intermediate and advanced stages
of PAD is that of the major histocompatibility complex
class II molecules –involved in human leukocyte antigen
mediated immune activation–are upregulated in inter-
mediate lesions whereas in advanced lesions they are not
differentially expressed [148].
Mitochondrial deficits
Beyond oxidative damage and systemic inflammation,
patients with PAD develop mitochondriopathy [9, 141].
Mitochondria are the major organelles for energy pro-
duction and dysregulation of their function is associated
with several diseases [149]. A variety of morphological
changes ranging from irregular distribution, hyper-
trophy, transverse reorientation and lipid vacuolisation
has been reported for the skeletal muscle mitochondria
in PAD patients [7, 150]. As a result, several studies con-
clude that mitochondrial respiration in PAD muscles is
compromised [7, 141, 151]. Electron transport chain com-
plexes (ETC) I, III and IV activities have been shown to de-
crease either simultaneously or in various combinations
[141, 150, 151]. Differences in the activity of ETC com-
plexes may be due to the severity of PAD, since the average
ancle-brachial index of the patients varied from 0.64 (inter-
mediate stage) to 0.34 (severe stage) [141, 150, 151].
Fig. 1 Manifestations of peripheral atherosclerosis in skeletal muscle structure, function and metabolic homeostasis. 4-HNE adducts: 4-hydroxy-2-nonenal
adducts; CD36: Cluster of differentiation 36; GCS: glycine cleavage system protein H; IFI30: Gamma-interferon-inducible lysosomal thiol reductase, IL-6: Inter-
leukin 6; MARCKS: myristoylated alanine-rich C kinase substrate; MCP1: monocyte chemotactic protein 1; NF-κB: Nuclear factor kappa-light-chain-enhancer
of activated B cells; PLA24A: phospholipase A2 group IVA; PLP: phospholipid transfer protein; TNFα: tumour necrosis factor α; TREM1: Triggering receptor
expressed on myeloid cells 1
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Similarly, in a mouse model of chronic ischemia, there is
reduced enzymatic activity of complex III and decreased
mitochondrial respiration [152, 153]. In a recent study,
defective mitochondrial autophagy in type I fibres was
reported in IC patients [154]. The authors suggested that
deficiency in the intermyofibrillar mitochondrial activity is
probably due to an increase in mitochondrial autophagy
rather than a decrease in mitochondrial respiration [154].
Furthermore, in patients with severe PAD (with an average
of ancle-brachial index 0.4) mitochondrial respiration re-
mains the same at baseline prior to addition of substrates,
whereas state 3 (i.e. ADP-stimulated respiration in the
presence of excess substrate) and state 4 respiration (i.e.
respiration in the absence of ADP and in presence of
a single substrate) are decreased [155]. Despite the
decrease in mitochondrial respiration, cytochrome c
oxidase activity may be within the normal range
[150]. The metabolic dysfunction of the skeletal
muscle mitochondria in vivo has been shown with the
accumulation of acylcarnitines not only in muscle but
in plasma as well [7, 156]. Several studies have re-
ported altered muscle metabolism in IC based upon
decreased post-exercise recovery rate of phosphocrea-
tine. This decrease is attributed to reduced oxygen
and not to deficient oxidative phosphorylation [157–
160]. Apart from changes in oxidative metabolism,
PAD patients with whole body insulin resistance ex-
hibit decreased glucose uptake in the calf muscle
[161]. Due to increased oxidative stress in the muscle,
mitochondrial damage has also been reported in PAD
muscle. The mitochondrial genome is prone to oxida-
tive injury as well as an accumulation of mitochon-
drial DNA deletions, which have been reported in
PAD patients, with the 4977 bp deletion being the
most common [162]. Thus, it appears that mitochon-
drial damage commences at an early stage of the dis-
ease and aggravates with disease progression and it
may correlate to increased oxidative stress.
Altered myofibre morphology and fibrosis
The myopathy in PAD is also characterised by the
alteration in the myofibre morphology. Several groups
have reported that myofibres reduce in size as the
disease advances and the loss in cross sectional area
(CSA) is correlated with the increase in oxidative dam-
age [9, 11, 150, 151]. However, others have failed to re-
port decreases in CSA, possibly due to differences in
disease severity among studies [6, 27, 163]. Along with
the decrease in size, myofibres lose their polygonal shape
[6, 9]. As PAD advances from IC to CLI, a decrease in
muscle force generating capacity is observed and muscle
degeneration proceeds with the appearance of nuclear
clumps, central nucleation, myofibre regeneration/de-
generation, a substantially wider range of sizes of the
myofibres, fibrosis and fat deposition [27]. Similar
changes such as reduced CSA, loss of the polygonal
shape, wide range of myofibre size and central nucle-
ation are features of the myopathy in the ischemic
mouse model with ligation of both femoral and iliac
arteries [152, 153]. Skeletal muscle satellite cells are a
local stem cell population that are indispensable of skel-
etal muscle fibre regeneration and repair after injury
[164, 165]. Satellite cell number decreases with age and
their regenerative capacity has been shown to either re-
duce or remain unaltered [166–168]. The role of satellite
cells in skeletal muscle regeneration of PAD has not re-
ceived full attention so far and remains to be established
in human studies [169]. However, it can be assumed that
the regenerative capacity of satellite cells may be limited
due to the decline of satellite cell number with ageing along
with the PAD pathophysiology i.e., ischemia in combination
with systemic inflammation, denervation, mitochondrial
dysfunction and increased oxidative stress and comorbidi-
ties (i.e. diabetes, hyperlipidaemia) [168–174]. A few studies
in preclinical models of PAD with hindlimb ischemia have
attempted to elucidate the regenerative capacity of satellite
cells [175–180]. On one hand, prolonged hypoxia was
shown to delay skeletal muscle regeneration, due to impair-
ment of satellite cell differentiation [177, 178]. On the other
hand, strategies that attenuate oxidative stress seem to aug-
ment the regenerative capacity of satellite cells [179, 180].
Notably, most of these studies have been conducted in
young and healthy mice without any comorbidities, where
the satellite cell potential is influenced only by ischemia.
Overall, the majority of studies on the regenerative
potential of satellite cells in PAD is based on preclinical
experimental models and extrapolation of findings to
humans should be made with caution [181].
Capillary density, chronic ischemia and impaired oxygen
supply
Atherosclerosis in the arteries of the lower limbs leads
to chronic ischemia of the muscle due to reduced oxy-
gen delivery [5]. Nonetheless, capillary density in PAD
patients with intermittent claudication has been reported
to remain unaltered or reduced [5, 163, 182]. In patients
with critical limb ischemia (CLI), capillary density is
further reduced, although some groups report an in-
crease of microvessel density when compared to inter-
mittent claudication, however the increase might be
attributed to the loss of myofibres [5]. Moreover, the
microvessels in CLI have abnormal structure and lose
their proliferative capacity [183]. VEGFA and the angio-
static VEGF165b factor seem to remain unchanged in
intermittent claudication whereas VEGF receptor 1 is
decreased [184]. However, an increase has been shown
in VEGFA and VEGF receptor 2 in the atrophic myofi-
bres which is local and correlates with the presence of
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inflammatory cells [185]. Angiostatic factors that are ele-
vated in the muscle of patients with severe PAD are
forkhead box protein O1 and matrix protein thrombos-
pondin 1, whereas mRNA levels of VEGF, VEGF recep-
tor 2, angiopoietin receptor 2 and HIF1α have a small
increase [5, 182].
PAD patients exhibit vascular endothelial dysfunction
not only in the large vessels but also in the microvascu-
lature [186–188]. ET-1 is a potent vasoconstrictor that is
produced by endothelial cells and has been shown to
contribute to the atherosclerotic narrowing of the lower
extremities [189]. Plasma levels and signalling of ET-1
are both elevated in CLI patients by 4-fold; ET-1 expres-
sion is increased in femoral artery and the endothelin 1
receptor A is co-localised with macrophages in the
plaque region [190]. In patients with IC, the basement
membrane of the lumina is thicker and may play a role
in impaired exercise tolerance [163]. Vascular smooth
muscle cells in IC express high levels of transforming
growth factor beta 1 (TGFβ1), a pro-fibrotic cytokine
[191]. As PAD progresses, the tunica media of affected
femoral arteries becomes thicker, there is collagen de-
position and fibroblast accumulation in the microvascu-
lature [163, 191]. Collagen deposition and TGFβ1 levels
correlate with the PAD stage [133, 191]. Apart from
endothelial dysfunction and collagen deposition in pa-
tients with intermittent claudication, endothelial cells in
the microvasculature have increased expression of cas-
pase 3 and elevated levels of apoptosis [192].
Consequently, peripheral atherosclerosis impacts on
skeletal muscle as outlined by increased oxidative damage,
inflammation, mitochondriopathy, loss of number and
function of myofibres, impaired capillary density and
apoptosis. Although ischemia– reperfusion cycles are con-
sidered the principal cause of skeletal muscle pathophysi-
ology in PAD, the impact of other comorbidities such as
hyperlipidaemia on endothelial dysfunction and skeletal
muscle pathophysiology should not be overlooked.
Experimental evidence on the skeletal muscle
pathophysiology of atherosclerotic mice
Although ApoE-/- and LDL receptor deficient (Ldlr-/-)
mice are widely used as models for systemic atheroscler-
osis, currently there is sparse scientific evidence evaluating
the skeletal muscle pathophysiology of these two experi-
mental models of atherosclerosis, as summarised in
Table 4 [46, 193]. ApoE-/- mice on normal chow diet have
decreased capillary density in the gastrocnemius from the
age of 12 weeks and nitric oxide bioavailability in skeletal
muscle arterioles declines from the age of 20 weeks with-
out changes in endothelial function [194, 195]. At 65 weeks
of age ApoE-/- mice exhibit extensive plaque formation in
the aorta and atherosclerotic plaques are also found in the
femoral arteries [196]. Blood perfusion does not seem to
be compromised between 2.5 and 8 months of age, while
exercise capacity either remains unaltered or decreases
[196, 197]. Curiously, one study reported a beneficial
phenotype with regard to inflammation, insulin sensitivity
and intramuscular lipid contents in ApoE-/- mice adminis-
tered a high-fat diet (i.e. 21% w/w fat corresponding to
40% kcal from fat) compared to wild type mice [198]. This
striking finding was attributed to a possibly attenuated
triglyceride-rich lipoprotein-derived fat delivery to skeletal
muscle due to ApoE deficiency, but mechanistic insights
remain to be established and validated in future studies.
On the other hand, ApoE-/- mice on a different high-fat
diet consisting of a higher percentage of fat (60% v/v fat)
exhibit elevated inflammation and greater levels of hydro-
gen peroxide in the muscle as compared with wild type
mice [199]. Ldlr-/- mice at the age of 22 weeks have de-
creased capillary density in the gastrocnemius, which is
less pronounced than in the ApoE-/- and the wall to lumen
ratio is elevated in the skeletal muscle arterioles [194].
Taken together these data suggest that although there may
be decreased capillarisation in the muscle of the murine
atherosclerotic models, neither glucose uptake nor inflam-
mation seems to be altered, despite the limited evidence
so far. The absence of characterisation of skeletal muscle
morphology and other biological parameters such as oxi-
dative stress and mitochondrial function remain to be elu-
cidated before valid conclusions can be drawn.
The study of skeletal muscle pathophysiology in PAD
has been modelled in animal studies using the “femoral
artery ligation” model of hind-limb ischemia, with the
majority of data being obtained from young and healthy
animals in the absence of any cardiovascular risk factors
or comorbidities associated with PAD such as hyperlip-
idaemia [152, 196]. These studies have provided valuable
information on the role of inflammatory and angiogenic
factors in skeletal muscle regeneration [200–204]. How-
ever, it has to be taken into consideration that revascu-
larisation (angiogenesis and arteriogenesis) following
femoral artery ligation in mice is rather a rapid process,
since blood perfusion is restored within a month after
an ischemic injury and cannot adequately simulate
chronic human PAD [152, 196]. Interestingly, when
femoral ligation is combined with iliac artery ligation, it
has been shown to simulate a more stable PAD model
over-time with chronic ischemia resembling severe
human PAD [152]. This model shows increased ROS
production, protein carbonyl content and 4-HNE ad-
ducts that indicate oxidative stress, as well as decreased
enzymatic activity of the mitochondrial antioxidant
superoxide dismutase 2 (SOD2) and mRNA levels of the
antioxidants catalase, superoxide dismutase 1 and 2, des-
pite increased SOD2 protein expression levels [152,
153]. It is also worth mentioning that there is no avail-
able model to fully recapitulate the pathophysiology of
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human PAD, not only due to the existence of comor-
bidities in PAD patients (such as hyperlipidaemia, dia-
betes and hypertension), but also due to the intra-
individual heterogeneity of the clinical disease [205].
The reader is directed to two interesting recent
reviews that discuss the challenges of translating ex-
perimental evidence into human disease [126, 205]. In
brief, in the femoral or iliac artery ligation model the
response to ischemia is not similar to the human
chronic PAD with animal models exhibiting, as
Table 4 Experimental evidence with manifestations of atherosclerosis in skeletal muscle
Reference Intervention Findings
[195] ♂ ApoE-/-, Ldlr-/- and WT (20wks); ND ↑ arterial pressure& Insulin resistance in Ldlr-/-; ↔ endothelial
vasodilation and VSMC reactivity in skeletal muscle arterioles;
↓ NO bioavailability in ApoE-/-
[194] ♂ ApoE-/-, Ldlr-/- and WT (12–13 and 22–23 wks); ND ↓ capillary density in gastrocnemius of ApoE–/- from 12wks and
in Ldlr-/- from 22wks; ↑ plasma oxidative stress and inflammatory
markers in ApoE-/- and Ldlr-/-; ↑ wall:lumen ratio in Ldlr-/-
[198] ♂ ApoE-/- and WT (18wks);
HFD (21% w/w) or ND for 12wks
↓ inflammation in AT and skeletal muscle of ApoE-/- HFD; ↓ Akt
phosphorylation in AT and skeletal muscle of WT HFD; ↑ crown
like structures in WT HFD; ↓ dietary lipid incorporation in adipose
tissue, skeletal muscle and liver in ApoE-/- HFD; No oxidative stress
in adipose tissue; ↑ TGs in skeletal muscle of WT HFD
[199] ♂ ApoE-/- and WT (16wks); HFD (60% v/v fat) or ND for 9wks ↑ H2O2 in liver and muscle of ApoE
-/- ND and HFD; ↑ H2O2 in AT
of ApoE-/- HFD; ↑ IL-6 in adipose tissue of WT HFD and ApoE-/-;
↑ TNFα of WT HFD and ApoE-/- HFD; ↑ crown like structures in
adipocytes of ApoE-/- HFD
[215] ♀ ApoE-/- (8-10months); Femoral artery ligation; ND Hyperaemic response to treadmill exercise similar to human
studies on PAD
[211] ApoE-/- (19-21wks); Iliac artery ligation; ND ↓ blood flow in the ischemic hindlimbs; ↑ capillarisation only in
quadriceps; ↑ fibre atrophy; ↑ of glucose uptake and
pro-inflammatory macrophages and T cells at early ischemic stages
[217] ♀ ApoE-/- and WT (8-10months); Hindlimb ischemia; ND ↓ myogenin levels in 7d post and ↑ MCP-1 levels at 14d post
ischemia/reperfusion in ApoE-/; Delayed skeletal muscle regeneration
[218] ♂ and ♀ ApoE-/- and WT (18-26wks); Notexin injury; ND ↑ fat lipid deposition and calcification; ↓ fibre size; Delayed skeletal
muscle regeneration
[216] ♀ ApoE-/- and WT (16-8wks); ND for WT and WD (1.25%
cholesterol, 15% w/w fat) in ApoE-/- for 10wks; Hindlimb
ischemia (removal of femoral artery and all major collateral
branches) and subsequent treatment for 21d with
miR-150 mimic peptide
↓ blood perfusion in ApoE-/- vs WT that improved with the miR-150
peptide; ↑ ambulatory impairment in ApoE-/- vs WT that decreased
with the miR-150 peptide; ↓ capillary density in ApoE-/- vs WT that
improved with the miR-150 peptide; ↓ number and functional activities
of PACs in ApoE-/- vs WT that improved with the miR-150 peptide
[221] ♀ Ldlr-/- (22wks) and ApoE-/- (36wks); Hindlimb ischemia
(double ligation of femoral artery) and subsequent treatment
with IFNAR1 Mab or IgG isotype (control); WD (16% w/w fat,
0.15% cholesterol) in Ldlr-/- for 8wks and for 24wks in ApoE-/-
↑ hindlimb perfusion restoration in Ldlr-/- treated with IFNAR1 Mab vs
Ldlr-/-; ↔ capillary density in Ldlr-/- treated with IFNAR1 Mab vs Ldlr-/-;
↔ atherosclerotic burden and lesion characteristics in Ldlr-/- treated
with IFNAR1 Mab vs Ldlr-/-; ↑ hindlimb perfusion restoration in ApoE-/-
treated with IFNAR1 Mab vs ApoE-/-; ↓ number of arterioles in ligated
limb of ApoE-/- treated with IFNAR1 Mab and ApoE-/- vs sham side of
ApoE-/- treated with IFNAR1 Mab and ApoE-/- respectively; ↔
atherosclerotic burden and lesion characteristics in ApoE-/- treated
with IFNAR1 Mab vs ApoE-/-
[220] ♂ Ldlr-/-, Ldlr-/-/CCR7-/-, WT (8-12wks); Hindlimb ischemia
with electrocoagulation of femoral artery
Blood flow recovery at 7d for WT, at 10d for LDLR-/- and in
Ldlr-/-/CCR7-/- was not fully recovered after 21d; ↔ number of
dendritic cells and T lymphocytes in spleen, lymph nodes and
blood in Ldlr-/- vs WT
[219] ♂ Ldlr-/- and WT (18wks); WT on ND and Ldlr-/- on HFD
(15.1% fat, 1.25% cholesterol) for 12wks; Iliac and femoral
artery ligation at 18wks; Subsequent treatment with heparin,
bFGF, heparin and bFGF or no treatment for 4wks
Blood flow of ischemic limb: ↑ in heparin treated, ↑↑ in bFGF treated
and ↑↑ in bFGF plus heparin in WT vs WT not treated and in Ldlr-/-:
↔ in heparin, in bFGF and not treated vs ↑ in bFGF plus heparin;
Blood perfusion in ischemic limb: ↓ in not treated Ldlr-/- vs WT not
treated; Mature vessels of ischemic limb: ↑ in heparin treated, ↑ in
bFGF treated, ↑ in bFGF plus heparin in WT vs WT not treated and
Ldlr-/- : ↑ in heparin, ↑ in bFGF and ↑↑ bFGF plus heparin vs Ldlr-/-
not treated
Abbreviations and Symbols: Akt Protein kinase B, ApoE-/- Apolipoprotein E knockout, AT Adipose Tissue, bFGF basic Fibroblast Growth Factor, CCR7 Chemokine C-C
receptor type 7, HFD High-fat Diet, H2O2 Hydrogen Peroxide, IFNAR1 Interferon α/β receptor type 1, IL-6 Interleukin 6, Ldlr
-/- Low-Density Lipoprotein Receptor knockout,
Mab Monoclonal Antibody, MCP1monocyte chemotactic protein 1, ND Normal Diet (chow diet), NO Nitric Oxide, PACs Bone marrow derived proangiogenic cells, PAD
Peripheral Arterial Disease, TBARS Thiobarbituric acid reactive substances, TNFa Tumor necrosis factor a, VSMC vascular smooth muscle cells, WD Western-type diet, WT
wild type; ↔ similar, ↓ decrease, ↑ increase; ♂: male; ♀: female; All strains WT, ApoE-/- and LDLR-/- are on a C57Bl/6 background
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mentioned earlier, an intense collateralisation that con-
tributes to a rapid restoration of blood flow and recovery
of muscle function which is not evident in PAD [201,
205]. This has been attributed to the formation of pressure
gradient between the ischemic and non-ischemic limb that
causes an increase in shear stress and blood flow in the
collateral arteries. In combination with the hypoxic envir-
onment, increased blood flow promotes infiltration of in-
flammatory cells that induce angiogenesis, arteriogenesis
and myogenesis by enhancing expression of VEGF up-
stream regulators, such as HIF-1α and NF-κB [127, 206–
208]. Moreover, muscle tissue necrosis in animal models
occurs in a greater degree than in PAD patients, where
chronic inflammation accompanied by insufficient col-
lateralisation lead to replacement of the damaged tissue
with fibrotic tissue [201, 209]. The aforementioned differ-
ences between acute arterial occlusion and PAD disease
may at least in part account for the unsatisfactory results
of angiogenic therapies in clinical trials [205, 210]. On the
other hand, gradual arterial occlusion with use of ameroid
constrictors is considered a potentially better model for
mimicking human ischemic disease, since it does not in-
duce tissue necrosis [209]. In addition, blood flow recov-
ery and inflammation are less profound compared to the
acute arterial occlusion model [209]. Apart from the type
of ischemia, the presence of comorbidities is also an im-
portant difference. Most PAD models comprise of healthy
young models, whereas development of PAD in human
patients is secondary to atherosclerosis and coexists with
several cardiovascular factors [211]. Since mouse models
of PAD are based on artery ligation for induction of ische-
mia, these models cannot entirely mimic human path-
ology in terms of fibrothrombotic lesion formation given
that acute arterial embolism does not occur spontaneously
[212]. Experimental femoral artery ligation mouse models
with either hypercholesterolaemia, metabolic syndrome,
hypertension or type 1 diabetes have delayed blood perfu-
sion when compared to wild type mice [213]. Thus, future
studies should take into account that a chronic model of
ischemia with comorbidities would be more pertinent
than the acute ischemia model [126, 202].
In this regard, a few studies have used ApoE-/- mice as
a model for PAD by inducing limb ischemia via femoral
artery ligation [211, 214, 215]. Specifically, ApoE-/- mice
subjected to ischemia followed by exercise have similar
hyperaemic response with exercising PAD patients and
exhibit delayed regeneration and increased inflammation
[214, 215]. In a recent study ApoE-/- mice on a western-
type diet and subsequent induced-ischemia, display im-
paired ambulation compared to wild type mice due to
delayed restoration of blood perfusion [216]. In the
hindlimb ischemia-reperfusion injury model, ApoE-/-
mice exhibit impaired muscle regeneration [217]. Simi-
larly, in notexin-induced muscle injury ApoE-/- mice
display impaired myofibre regeneration with increased
fat infiltration and calcification. The authors concluded
that the delay in muscle healing is due to impaired
macrophage phagocytic activity [218]. Ldlr-/- mice are
also used as a model for PAD by ligating the femoral ar-
tery and inducing limb ischemia [219–221]. Ldlr-/- mice
on a western-type diet and subjected to ligation of both
femoral and iliac arteries have reduced blood perfusion
as compared to wild type mice [219]. In a different
model of ischemia induced by coagulation of the fem-
oral artery, Ldlr-/- mice show complete blood flow re-
covery at 10 days after injury, whereas wild type mice
recover fully after 7 days [220]. However, a direct
comparison of genotypes in this study was not per-
formed. Taken together these data suggest that both
experimental models of atherosclerosis are suitable for
the study of PAD. To the best of our knowledge no
studies have compared both atherosclerotic mouse
models of the same age and diet to draw certain con-
clusions as to which model may be more beneficial
for the study of PAD.
NADPH Oxidases in vascular disease
Reactive oxygen species are a diverse class of reactive
chemical molecules that consist of highly reactive oxy-
gen atoms [222]. ROS play an important role in multiple
physiological processes by regulating enzymatic activ-
ities, transcription factors and nucleic acids that are in-
volved in cell growth, proliferation and survival [222].
ROS are usually produced as a ‘by-product’ by diverse
sources in the cell, such as respiratory enzymes, lipooxy-
genases, eNOS and xanthine oxidase [25, 222]. NADPH
oxidases are the only enzymes that produce primarily
ROS [25]. There are 7 homologues of Noxs that have
been identified in the mammalian species, specified
Nox1 to Nox5 and Dual Oxidases (Duox) 1 and 2 [223].
Noxs are multimeric protein complexes and the majority
of them produces superoxide via their catalytic Nox sub-
unit that is membrane bound and transfers electrons
from cytosolic NADPH to molecular oxygen [25, 222].
Nox4, Duox1 and 2 seem to produce hydrogen peroxide
due to dismutation of superoxide [222]. Nox1 to Nox3
enzymatic activities are regulated by the cytosolic pro-
teins NADPH oxidase activator 1 (Noxa1) and NADPH
oxidase activator 2 (p67phox) as well as scaffolding pro-
teins that attach the cytosolic activators to the Nox cata-
lytic subunits neutrophil cytosol factor 1 (p47phox),
neutrophil cytosol factor 4 (p40phox) and NADPH oxi-
dase organiser 1 (Noxo1) [224]. Nox1 interacts preferen-
tially with Noxa1 (p67phox homologue) and Noxo1
(p47phox homologue) but can interact with p47phox
and Nox2 interacts mainly with p47phox and p67phox
[224]. The GTPases Ras-related C3 botulinum toxin
substrate 1 and 2 (Rac1 and Rac2) are important for
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Nox activation, apart from Nox4 that is constitutively
active [223]. However, Noxs as monomers are inactive
and rely on the interaction with the transmembrane
scaffolding protein superoxide-generating NADPH oxi-
dase light chain subunit (p22phox) to be activated, with
the exception of Nox5, Duox 1 and 2 [223, 224].
Noxs were first identified in phagocytic cells and they are
responsible for the respiratory burst that is essential for in-
nate immune response and phagocytosis of pathogens [25,
222]. In the vascular wall, Noxs are a significant source of
ROS production. Endothelial cells express Nox1, Nox2,
Nox4 and Nox5, vascular smooth cells express Nox1, Nox4
and Nox5 while adventitial fibroblasts express Nox2 and
Nox4 [25, 222]. In vascular diseases such as atherosclerosis,
in diabetes and hypertension, there is an increase in ROS
production from the vasculature and is considered an im-
portant initiator of atherogenesis by promoting proinflam-
matory pathways and oxidative stress that lead to
endothelial dysfunction [25, 225, 226]. Indeed, with the use
of transgenic and knockout mice Nox1 and 2 were shown
to play an important role in atherosclerosis [57, 226]. Con-
sequently, the role of Noxs in atherogenesis has lately re-
ceived much attention as summarised in Table 5 [226, 227].
ApoE-/-/p47phox-/- double knockout mice at the age of
16 weeks have similar total plasma cholesterol levels and
decreased vascular superoxide production but the same le-
sion area in the aortic sinus with ApoE-/- mice [228].
Although the lesion area is similar in the aortic sinus,
ApoE-/-/p47phox-/- double knockout mice at the age of
30 weeks have reduced lesion area by 75% in the whole
aorta and under a high-fat diet the reduction reaches 50%
at the age of 18 weeks [90]. Allogenic bone marrow
transplantation between ApoE-/-/p47phox-/- and ApoE-/-
followed by a high-fat diet (42% kcal from fat) leads to
decrease of lesion coverage (>50%), smaller lesion size,
fewer macrophages and lower endothelial superoxide
production in both groups [229]. ApoE-/- mice with bone
marrow from ApoE-/-/p47phox-/- have lower levels of
oxidised LDL and ApoE-/-/p47phox-/- with bone marrow
from ApoE-/- have reduced expression of cellular adhesion
molecules. These findings suggest that on one hand the
NADPH oxidase activity contributes to lesion formation
and on the other hand vascular wall cells and bone
marrow promote atherogenesis through different pro-
cesses [226, 229]. Although the studies on p47phox
deficiency give an insight into the role of Noxs in
atherosclerosis, it is difficult to dissect the particular
role of individual Nox homologues to the above find-
ings, since Nox2 interacts mainly with p47phox and
Nox1 mainly with Noxo1 but the interaction of Nox1
with p47phox cannot be ruled out [226].
The role of Nox1 in atherosclerosis is not fully eluci-
dated and there are contradictory data from studies on
Nox1 depletion. Sheehan et al. reported that Nox1
deficiency in ApoE-/- mice (Nox1-/y/ApoE-/-) fed a high-
fat diet (42% kcal from fat) exhibited reduced superoxide
production and a decreased lesion area by 35% in the
aortic arch and 28% in the entire aorta. Furthermore, the
lesions contained less macrophages [230]. On the con-
trary, Nox1-/y/ApoE-/- mice fed a western-type diet ex-
hibited similar lesion coverage throughout the aorta and
the thickening of the intima was larger at the level of the
aortic sinus compared to ApoE-/- mice [231]. Addition-
ally, the lesions in the aortic sinus appear to be more un-
stable implying that Nox1 has a protective role in
atherosclerosis [231]. Similarly, Nox1 deficiency in the
aortas of diabetic ApoE-/- mice reduced lesion coverage,
attenuated macrophage infiltration, expression of pro-
inflammatory chemokines and ROS production, while
it did not have any effect in ApoE-/- mice [232].
Thus, Nox1 seems to be important for the progres-
sion of diabetes-associated atherosclerosis while in
atherosclerosis there are inconsistent data as to
whether Nox1 is protective and further research is
needed.
Nox2 (previously called gp91) deletion in ApoE-/- mice
on a normal chow diet does not seem to impact on le-
sion area and lipid deposition in the aortic sinus at the
age of 24 weeks with male ApoE-/-/gp91-/- mice having
decreased HDL levels and increased LDL levels by 60%
compared to ApoE-/- whereas these differences in
plasma cholesterol were not evident in female double
knockout mice [233]. ApoE-/- mice overexpressing Nox2
specifically in the endothelial cells (Nox2Tg ApoE-/-
mice) on a normal chow diet have elevated vascular
superoxide production, but surprisingly, the lesion area
is equivalent to ApoE-/- mice with comparable lesion
composition and progression [225]. Interestingly,
VCAM1 expression–an inflammatory marker of endo-
thelial cells involved in the development of atheroscler-
osis–and macrophage recruitment are both increased at
the age of 9 weeks to similar levels seen in ApoE-/- mice
[225]. Therefore, it has been suggested that Nox2 plays a
significant role to the initiation of lesion formation and
not of lesion progression [225]. On the other hand,
Nox2-/y/ApoE-/- male mice administered a western-type
diet (21% w/w fat, 0.15% cholesterol) either for 7 or
14 weeks have similar plasma cholesterol levels with
ApoE-/- and although the lesion area coverage in the
aortic sinus is similar, a 50% decrease in lesion area
throughout the aorta is evident [57]. Furthermore,
Nox2-/y/ApoE-/- exhibit reduced vascular superoxide pro-
duction by 75% and improved nitric oxide bioavailability
compared to ApoE-/- [57]. Importantly, ApoE-/- mice on a
western-type diet (15.8% w/w fat, 1.25% cholesterol) and
treated with a Nox2-specific inhibitor, the Nox2ds-tat
peptide, showed decreased lesion coverage throughout the
aorta and the carotid arteries [94]. Moreover, vascular
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Table 5 Targeting NADPH oxidases in skeletal muscle
Reference Intervention Findings
[94] ♂ ApoE-/- (16wks); ND or HFD (15.8% fat, 1.25% cholesterol)
for 8wks; For 4wks; HFD + Nox2 inhibitor peptide (Nox2ds-tat) or
HFD plus control sequence (scrambled, Scr)
↑ cholesterol and TGs in Scr and Nox2ds-tat; ↑ O2
.- production in
carotid arteries and atherosclerotic lesions throughout the aorta
of HFD and Scr but ↓ in Nox2ds-tat; ↓ mRNA expression of p47phox
and p22phox in Nox2ds-tat vs Scr; ↑ gene expression of VEGF, HIF1α,
visfatin and MMP9 in carotid arteries of Scr, ↓ in Nox2ds-tat; ↑ MMP9
activity and protein levels in carotid arteries of Scr vs ND and ↓
in Nox2ds-tat
[90] ♂, gp91-/-, ApoE-/- and ApoE-/-/p47-/- (18wks); ND and HFD
for 10wks (15% w/w fat, 34% kcal from fat)
↓ p47-/- in gp91-/- response of SMC in growth factors in vs WT;
↓ O2
.- expression in aortas of p47-/- vs WT; ↔ ApoE-/- and
ApoE-/-/p47-/- in serum lipid levels; ↓ lesion area throughout the
aorta, ↔ in the aortic sinus in ApoE-/-/p47-/- vs ApoE-/- HFD
[228] ♂ ApoE-/-, ApoE-/-/p47-/- (16wks); ND ↔ basal O2
.- levels in aorta that ↓ in ApoE-/-/p47-/- after inhibition
of SOD; ↔ aortic lesion area, serum blood levels and aortic
blood pressure
[233] ♂ and ♀ WT, gp91-/- (30wks), ApoE-/-, ApoE-/-/gp91-/- (24wks);
HFD for 20wks in WT and gp91-/- (15% w/w, 37.1% kcal from
fat, 1.25% cholesterol, and 0.5% sodium cholate); ApoE-/-
and ApoE-/-/gp91-/- in ND
↓ O2
.- production from peritoneal macrophages in gp91-/- and WT;
↔ gp91-/- and WT in plasma lipid profile and lesion area (♀: ↓
plasma TGs and ↑ lesions);
↓ plasma cholesterol & TGs (only in ♂ ApoE-/-/gp91-/- vs ApoE-/-);
↓ 2-fold HDL and ↑ 60% of LDL in ApoE-/-/gp91-/- vs ApoE-/-;
↔ aortic sinus lesion area in ApoE-/-/gp91-/- vs ApoE-/-
[57] ♂ApoE-/- & (12 and 19wks); WD (21% w/w fat, 40% kcal and
0.15% cholesterol) for 7 and 14wks
↓ superoxide production, ↑ NO bioavailability and ↓ lesion coverage
in Nox2-/yApoE-/-
[229] ♂ and ♀ ApoE-/-, ApoE-/-/p47-/- ; Bone marrow transplanted
mice for 4wks in ND and then in WD (42% kcal from fat,
0.2% cholesterol) for 12wks; (Control: Bone marrow
transplantation from ApoE-/- to ApoE-/-)
↓ VWO & BMO in atherosclerotic coverage, lesion size with fewer
macrophages and O2
.-production vs Control; ↔ BMO & VWO in total
cholesterol, TGs, expression of p22phox and catalytic subunits of
Nox1 and Nox4; ↓ BMO in oxLDL levels vs VWO and Control; ↓ VWO
in gene expression and immunostaining of VCAM1, iCAM1 and P
Selectin vs BMO and control
↓ ApoE-/-/p47phox-/- in neointimal hyperplasia after femoral injury
vs ApoE-/-; ↑ VSMC proliferation in ApoE-/- vs ApoE-/-/p47phox-/-
[225] ApoE-/-, Nox2Tg ApoE-/-(9-24wks); Sex, NS; ND ↑ O2
.- in Nox2Tg ApoE-/-; ↑ VCAM1 and macrophage recruitment in
Nox2Tg ApoE-/- only at 9wks; ↔ total plasma cholesterol, LDL, HDL,
TGs, OxLDL lesion area, lesion progression and composition,
macrophage recruitment and lipid deposition in Nox2Tg ApoE-/-;
Treatment with AngII for 4wks ↑ lesions in a dose-dependent
manner similarly
[231] ♂ ApoE-/- and Nox1-/yApoE-/- (12, 19 and 26wks); WD
(21% w/w fat and 0.15% cholesterol) for 7,14, or 21wks
↑ VLDL/LDL, TGs, O2
.- and intimal thickening in aortic sinus in
Nox1-/yApoE-/-; ↔ plaque area in Nox1-/yApoE-/- ; ↓ collagen,
SMCs and ↑ MMP-9 in aortic sinus lesions in Nox1-/yApoE-/-
[230] ♂ ApoE-/- and Nox1-/yApoE-/- (24wks); HFD for 18wks
(42% kcal from fat)
↓ aortic lesions, O2
.- production and number of macrophages in
lesions in Nox1-/yApoE-/-
[91] ♂ WT (28 wks old); HFD for 8wks (60% kcal from fat) or ND,
a HFD subgroup treated with apocynin
↑ plasma insulin, glucose and HOMA-IR in HFD; ↓ glucose uptake
from muscle and ↑ H2O2 in myofibres after insulin stimulation of
HFD; GSH/GSSG ratio in muscle of HFD; ↑ Nox2 and p47phox
protein expression in HFD muscle; ↓ insulin resistance in whole
body and muscle and p47phox and Nox2 levels in muscle of
HFD after treatment with apocynin
[239] ♂ WT and Nox2-/y (18 and 42wks); ND or HFD (45% kcal
from fat) for 3 or 9 months
↑↑ WT HFD and ↑ Nox2-/y in BW, HOMA-IR and GTT; ↔ oxidative
and glycolytic myofibres; ↑ Nox2, p22phox, p67phox and O2
.-
production in the muscle of WT HFD; ↑ Nox2-/y HFD and ↓ WT
HFD in Glut4 and Akt phosphorylation of muscle; ↑ Nox2, p22phox,
p67phox and ↓ phosphorylated Akt and glucose uptake in myoblasts
treated with palmitate or high concentration of glucose; ↓
phosphorylated Akt and glucose uptake in shRNA Nox2-expressing
myoblasts after treatment with H2O2
Abbreviations and Symbols: Akt Protein Kinase B, AngII Angiotensin II, ApoE-/- Apolipoprotein E knockout, ApoE-/-/gp91-/- Double Apolipoprotein E
knockout and gp91 knockout, ApoE-/-/Nox1-/y Double Apolipoprotein E knockout and Nox1 knockout, ApoE-/-/p47-/- Double Apolipoprotein E knockout and
p47 knockout, BMO Bone Marrow transplantation from ApoE-/-/p47phox-/- to ApoE-/-, BW Body Weight, DHE Dihydroethidium, Glut4 Glucose Transporter
Type 4, gp91-/- gp91 knockout, GSH Glutathione reduced, GSSG glutathione oxidised, GTT Glucose Tolerance Test, H2O2 Hydrogen Peroxide, HDL High-
density lipoprotein, HIF1a Hypoxia Inducible Factor 1a, HFD High-fat Diet, HOMA-IR Homeostatic Model Assessment for Insulin Resistance, iCAM1 Intercellu-
lar adhesion molecule 1, LDL Low-density lipoprotein, MMP9 Matrix metalloproteinase 9, Nox2 nicotinamide adenine dinucleotide phosphate-oxidase 2,
Nox2-/y Nox2 Knockout, Nox2Tg ApoE-/- ApoE-/- with overexpression of Nox2 specifically in Endothelial Cells, ND Normal Diet (chow diet), NS Not Specified,
O2
.- Superoxide, oxLDL Oxidised LDL, p47phox-/- p47phox knockout, shRNA Nox2-expressing Short Hairpin RNA to silence Nox2 expression, SOD Superoxide
Dismutase, SMC Smooth Muscle Cells, TGs Triglycerides, VCAM1 Vascular cell adhesion molecule 1, VEGF Vascular Endothelial Growth Factor, VLDL Very
low-density lipoproteins, VSMC vascular smooth muscle cells, VWO Bone Marrow transplantation from ApoE-/- to ApoE-/-/p47phox-/-, WD Western-type diet,
WT wild type; ↓ decrease, ↑ increase, ↔ similar; All strains WT, ApoE-/-, ApoE-/-/gp91-/-, gp91-/-, Nox2Tg ApoE-/-, Nox1-/yApoE-/-, Nox2-/yApoE-/- and p47-/-are
on a C57Bl/6 background
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superoxide production and mRNA expression of
p47phox and p22phox were decreased in the carotid
arteries [94]. The Nox2ds-tat peptide is a 9 amino
acid sequence (similar to the cytosolic B-loop of
Nox2) and inhibits the interaction between Nox2 and
p47phox. Nox2ds-tat suppresses superoxide produc-
tion in endothelial cells and its efficacy has been
established both in vitro and in vivo [234–236]. This
evidence suggests that Nox2 may be an important
contributor in the initiation of atherogenesis and its
role in the progression of atherosclerosis remains to
be further elucidated [57, 94, 225].
Skeletal muscle expresses two Nox members i.e. Nox2
and Nox4 although in cultured muscle cells apart from
Nox2 and 4 expression, Nox1 and Duox 1 and 2 expres-
sion has been also reported [237]. Nox2 is localised in
the sarcolemma, transverse tubules and possibly in the
sarcoplasmic reticulum whereas Nox4 is localised in
mitochondria and sarcoplasmic reticulum [138, 237,
238]. Noxs along with mitochondria are considered to
be the major sources of ROS production in the skeletal
muscle [138]. In particular, Nox2 is an important source
of ROS production in response to skeletal muscle con-
traction and mechanotransduction as well as in insulin
signalling [237]. In several chronic cardiac and skeletal
muscle diseases, such heart failure and ageing-induced
sarcopenia there is an upregulation of Nox2 subunits in
the muscle and recently Nox2 was recognised as a major
contributor to the pathology of Duchenne Muscular
Dystrophy [237]. Sparse evidence also suggests a role for
Nox2 in insulin resistance in the muscle [237]. An in-
crease in ROS production and Nox2 protein expression
by 1.6-fold and p47phox subunit by 7-fold has been
found in muscle of insulin resistant C57Bl/6 mice caused
by high-fat feeding for 8 weeks [91]. Nox2 knockout
mice on a high-fat diet (60% kcal from fat) for 9 months
showed improved glucose uptake and reduced ROS pro-
duction compared with wild type mice [239]. Conse-
quently, Noxs and especially Nox2 play an important
role in muscle oxidative stress both in physiological and
pathophysiological conditions. Exciting recent research
is focusing on the pharmacological inhibition of Noxs by
small molecule inhibitors for counteracting the athero-
thrombotic process [240–243]. However, most animal stud-
ies employing small molecule inhibitors such as the Vaso-
pharm triazolo pyrimidine derivatives, apocynin and diphe-
nyleneiodonium either lack specificity or have adverse ef-
fects [241, 244, 245]. Recently ebselen and its analogues
were identified as specific inhibitors of Nox2 and of Nox1,
with the JM-77b derivative having a greater specificity for
Nox2 than Nox1, Nox4 and Nox5 [240–242]. Similarly,
GKT136901 and GKT137831, a pyrazolopyridine class of
compounds, are specific inhibitors of both Nox1 and Nox4.
Administration of the GKT137831 inhibitor has been
shown to reduce liver fibrosis and diabetic atherosclerosis
in animal studies [232, 241]. It is worth mentioning that
such compounds are the first oral inhibitors that are in
phase II clinical trials for treatment of diabetic nephropathy
[241, 246]. However, selective inhibition of the Nox homo-
logues is essential in order to eliminate opposing effects
and complications in cardiovascular pathologies [26, 241,
247, 248]. Collectively, although small molecule inhibitors
are a promising new area, further validation of their phar-
macokinetic and pharmacodynamic profile is of paramount
significance so as to proceed in clinical trials [241].
Atherosclerosis and skeletal muscle deficits;
possible links through vasculature, ischemia and
inflammation
The “metabolic hypothesis” was introduced almost three
decades ago to suggest a direct relationship between the
local blood flow and the metabolic demand of the
muscle [249, 250]. The crosstalk between blood flow and
tissue metabolism is brought about by products of ATP
turnover released by the muscle, in order to regulate the
vascular tone. More recently NO, prostaglandins and
endothelium-derived hyperpolarization factors secreted
by endothelial cells were also included as potent regula-
tors of vascular tone and perfusion in the skeletal
muscle [251–254]. Apart from the nutrient and oxygen
supply, the interplay between the vasculature and the
skeletal muscle is evident in satellite cell regulation.
Satellite cells are in close proximity with capillaries and
their number correlates with the number of capillaries
per myofibre [255]. In vitro studies have shown that
growth factors, such as insulin-like growth factor (IGF-
1), hepatocyte growth factor and basic fibroblast growth
factor, derived from endothelial cells promote the activa-
tion of satellite cells in a paracrine way and in turn
satellite cells have proangiogenic activity mainly through
the secretion of VEGF [256, 257]. Similarly, angiopoietin
1 that is expressed by satellite cells, smooth muscle cells
and pericytes may contribute not only to vessel stability
but also to satellite cell quiescence [255]. Additional evi-
dence suggests that skeletal muscle acts as a secretory
organ and cross talks to vasculature [123, 258]. Several
cytokines, such as IL-6, IL-10, IL-15, IL-7 as well as
other factors such as myostatin and follistatin are se-
creted by muscle cells and act upon cells in both an
autocrine and paracrine way [258, 259]. It was recently
shown that the endothelium contributes to muscle
regeneration after eccentric exercise by expressing
leukemia inhibitor factor (LIF), fraktalkine, VEGF and
IL-8 that contribute to immune cell infiltration and
angiogenesis, two essential processes for muscle regener-
ation [259]. Myokines–defined as those factors secreted
by the skeletal muscle per se–have been speculated to
exhibit an endocrine function affecting other organs
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such as the liver and adipose tissue, although this line of
thought remains to be further established [258, 259].
Most studies that investigate the impact of atheroscler-
osis on PAD focus on haemodynamic changes from
ischemia-reperfusion cycles [14, 144, 260–264]. Skeletal
muscle pathophysiology of ischemia-reperfusion cycles
has been recently reviewed in detail amalgamating data
from both human and animal studies of PAD [134]. In
particular, chronic ischemia causes deprivation of oxygen
and nutrient supply, leading to several changes in skel-
etal muscle metabolism. Such changes include: i) de-
crease in mitochondrial respiration, ii) increase in ROS
production, iii) accumulation of products of metabolism
such as H+ and Ca+ and iv) dysregulation of myocellular
ions, (i.e. K+ and Na+) that further compromise cellular
function [134]. The onset of reperfusion has also a nega-
tive impact on the ischemic muscle mainly due to a
rapid increase in oxygen supply [134]. Higher amounts
of oxygen trigger overproduction of ROS by endothelial
cells, pro-inflammatory cells and by myocytes with the
latter producing ROS mainly due to uncoupling of mito-
chondrial respiration [134]. Furthermore, satellite cells
in the hindlimb ischemia model seem to have decreased
expression of myogenic markers of differentiation which
is restored once reperfusion is established [265]. This
finding further highlights the interaction between the
vasculature and the skeletal muscle.
There is currently sparse experimental evidence on the
effect of central atherosclerosis on skeletal muscle
biology. Hyperlipidaemia–a major risk factor of athero-
sclerosis and PAD–is considered an important step in
atherogenesis [23, 266–268]. Excess cholesterol leads to
endothelial dysfunction that in turn promotes expression
of pro-inflammatory cytokines, such as TNFα and IL-6
and ROS overproduction [23, 266]. ROS production
from several enzymes such as NADPH oxidases,
xanthine oxidase and uncoupled eNOS lead to oxidative
stress and activation of NF-κB, which enhances the
expression of pro-inflammatory cytokines, such as TNFα
and IL-6 and reinforces further production of ROS
[269–272]. In addition, pro-inflammatory cytokines pro-
mote further activation of redox-sensitive transcription
factors by means of several signalling pathways that
contribute to additional ROS production from the
vasculature [273, 274].
Since hyperlipidaemia impacts on the liver and adipose
tissue, it can be speculated that skeletal muscle can be af-
fected as well taken into account the molecular crosstalk
among these metabolically active tissues [147, 275–278].
In fact, triglyceride accumulation in the adipose tissue
leads to increased expression of pro-inflammatory cyto-
kines and adipokines, such as resistin and visfatin that be-
yond promoting atherosclerosis, could potentially induce
oxidative stress in skeletal muscle [147, 276–279].
Systemic low grade inflammation is evident in both Ldlr-/-
and ApoE-/- experimental atherosclerotic mouse models
with increased plasma concentrations of TNFα, IL1β and
MCP1 [194]. Pro-inflammatory cytokines in circulation
could trigger redox-sensitive transcription factors in
skeletal muscle promoting ROS and pro-inflammatory
cytokine production from muscle cells in a similar way as
in insulin resistant patients [277, 278]. Collectively, it can
be speculated that systemic low grade inflammation may
also affect skeletal muscle metabolic homeostasis in PAD.
Another factor that may be affecting muscle patho-
physiology is the peptide hormone angiotensin II that
has been found to contribute to atherogenesis and pro-
gression of atherosclerosis [280]. Angiotensin II is a po-
tent vasoconstrictor and pro-inflammatory peptide that
induces vascular endothelial dysfunction in multiple
ways by enhancing i) the secretion of pro-inflammatory
cytokines, ii) production of ROS, iii) expression of oxi-
dised LDL receptor and iv) expression of matrix metallo-
proteinases from the endothelium [280]. Moreover,
angiotensin II and its receptors are expressed in human
atherosclerotic plaques from the majority of the cells
that reside in the plaque such as macrophages, endothe-
lial cells and smooth muscle cells [280]. Similarly, angio-
tensin II and its receptor angiotensin II type-1 receptor
(AT1) are expressed in lesions of atherosclerotic animal
models [280]. The substantial role of angiotensin II in
atherosclerosis progression has been demonstrated in
AT1-/-/ApoE-/- mice that exhibited diminished athero-
sclerotic burden and vascular ROS production [281].
Importantly, treatment of ApoE-/- mice with an AT1 re-
ceptor antagonist inhibited progression of atheroscler-
osis [281]. In a different study, treatment of ApoE-/-
mice with an AT1 receptor antagonist and simultaneous
infusion with angiotensin II inhibited progression of
atherosclerosis by decreasing the expression of pro-
inflammatory markers and ROS production from the
endothelium [282]. The aforementioned effects of angio-
tensin II on progression of atherosclerosis are independ-
ent of systemic blood pressure changes, since treatment
of ApoE-/- mice with a calcium antagonist or a vasodila-
tor did not affect lesion progression [281, 282].
Angiotensin II might affect skeletal muscle homeosta-
sis in atherosclerosis, not only due to its significant im-
pact on the vasculature, but due to a rather direct effect
on skeletal muscle. For instance, angiotensin II in
congestive heart failure and chronic kidney disease
contributes to muscle wasting [283, 284]. This may be
explained by a downregulation of the Akt/mTOR/
p70S6K pathway and activation of apoptotic pathways
(e.g. activation of caspase 3, proteins ubiquitination, re-
duction of Bad phosphorylation and increase in cytosolic
cytochrome c) [283]. Specific overexpression of IGF-1 in
skeletal muscle attenuated the effects of angiotensin II
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and it was concluded that downregulation of IGF-1 may
be the primary cause of muscle wasting in congestive
heart failure and chronic kidney disease [283]. More re-
cently angiotensin II was shown to cause mitochondrial
dysfunction by suppressing AMPK phosphorylation
through protein phosphatase 2C-alpha and thus redu-
cing mitochondrial biogenesis, activity of complex IV,
expression of complex V and inhibiting mitophagy [284].
In addition, mitochondrial dysfunction from angiotensin
II was also induced through AMPK independent path-
ways mainly by inhibition of proteins that are associated
with mitochondrial fission and fusion [284]. Notably,
angiotensin II may increase oxidative stress in skeletal
muscle by inducing Noxs and reduces satellite cell-
driven muscle regeneration [237, 285, 286]. Angiotensin
II, in particular, inhibits Notch signalling and cyclins D1
and E in satellite cells, thus compromising the satellite
cell proliferation and differentiation potency [286]. Con-
sequently, angiotensin II may potentially affect skeletal
muscle physiology in the context of PAD, although the
mechanistic links between atherosclerosis and skeletal
muscle remain to be discovered.
Conclusions
Peripheral atherosclerosis has serious implications for
human health and impacts in several tissues including
skeletal muscle. Accumulating data over the past decade
from human studies with PAD patients and some evi-
dence from rodent studies have improved our under-
standing about the pathophysiology of skeletal muscle in
the context of atherosclerosis. There is a number of
structural, functional, biochemical and metabolic deficits
taking place in the skeletal muscle that compromise its
homeostasis and functional capacity. There are signs of
myopathy, fibrosis, mitochondrial de-regulation, oxida-
tive stress, inflammation and apoptosis, followed by im-
paired capillary density, chronic ischemia and muscle
pain. Such manifestations in skeletal muscle may in turn
compromise the capacity to generate force or ambulate
and impact on the quality of life. By identifying the
crossroads between skeletal muscle metabolism, dietary
challenges and peripheral atherosclerosis we will be able
to better prepare new strategies to cope with such ab-
normalities and improve muscle physiology and quality
of life in patients with cardiovascular complications such
as peripheral atherosclerosis. Experimental models of
atherosclerosis with a skeletal muscle phenotype may
offer an attractive tool to develop new strategies to com-
bat the manifestations of atherosclerosis in peripheral
tissues. NADPH oxidases are key components of in-
creased cellular oxidative stress and their role in athero-
genesis has received much attention recently. Several
studies have shown the beneficial effect of Nox2 defi-
ciency in the initiation and lesion progression in the
aorta of the ApoE-/- mice. Several inhibitors have been
developed in an attempt to reduce atherosclerosis, with
Nox2ds-tat recently showing that treatment of ApoE-/-
with this peptide reduced lesion size in the aorta and ca-
rotid arteries [94]. The impact of Nox inhibition on skel-
etal muscle and whole body levels of oxidative stress in
the context of atherosclerosis or other cardiovascular
disorders remains to be established.
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